MULTIPLY YOUR VOICE

SHARE

Stocks Soar On Fauci-Touted Remdesivir Study Despite Marginal Survival Benefit, Snubs Lancet Findings

Corona Virus Treatment

"Update (13:15ET): The NIAD has released a statement on the Gilead remdesivir study. The statement repeated some of the numbers Dr. Fauci shared at the press conference - that patients who took remdesivir saw 31% faster time to recovery than the placebo group, while mortality rates "improved" to 8% from 11.6% an improvement of 3.6 percentage points, which Dr. Fauci acknowledged wasn't "statistically significant.""

 

See the first comment for an unencouraging update.

https://www.zerohedge.com/markets/futures-surge-positive-gilead-headlines

Showing 1 reaction

Please check your e-mail for a link to activate your account.